Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Commercial Sponsor
BeiGene Australia Pty Ltd
Summary
This is a non-randomised, open-label trial with two cohorts: one for patients with acute myeloid leukaemia (AML) and one for patients with myelodysplastic syndromes (MDS). Both cohorts will receive treatments in two phases. Phase one is testing two different treatment cycles of BGB-11417 (orally) and azacitidine (via intravenous [IV] or subcutaneous [SC] injection). In Phase 2, the cycle determined in the initial phase will be applied, or a subset of patients may receive a modified treatment.